Influenza viruses have raised public health concerns by seasonal epidemics and intermittent pandemics. Vaccination is considered as the most effective method for preventing influenza infection in humans. Current influenza vaccines are mostly produced in fertile chicken eggs. However, disadvantages of egg-based vaccines, such as egg dependency, labor-intensive manufacturing system, and huddle for large-scale output, allow us to make an alternative method. A cell-culture platform may be a fine alternative for the next generation vaccine technique. Compared with a classical egg-based method, cell-grown vaccines provide stable pipeline even in the pandemic situation with shorter lead-in times. In addition, cell-grown vaccines are flexible for altering production scales because stocked cell batches can be easily sub-cultured in large quantity without worrying avian diseases and a resultant decrease in egg production. By World Health Organization, MDCK, PER.C6, and Vero cells are only recommended for manufacturing influenza vaccines. In this review, we discuss the necessity, immunogenicity, and efficacy of cell-grown influenza vaccines compared with egg-based vaccines.
The first cell-culture based seasonal vaccine in U.S. 
